BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang F, Xu Y, Zhao B. NLRC5: new cancer buster? Mol Biol Rep 2020;47:2265-77. [PMID: 31925644 DOI: 10.1007/s11033-020-05253-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Liao X, Wang W, Yu B, Tan S. Thrombospondin-2 acts as a bridge between tumor extracellular matrix and immune infiltration in pancreatic and stomach adenocarcinomas: an integrative pan-cancer analysis. Cancer Cell Int 2022;22:213. [PMID: 35701829 DOI: 10.1186/s12935-022-02622-x] [Reference Citation Analysis]
2 Lu T, Xu R, Wang C, Zhao J, Peng B, Wang J, Zhang L. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development. Front Genet 2022;13:853113. [DOI: 10.3389/fgene.2022.853113] [Reference Citation Analysis]
3 Torkamandi S, Bahrami S, Ghorashi T, Dehani M, Bayat H, Hoseini SM, Rezaei S, Soosanabadi M. Dysregulation of long noncoding RNA MEG3 and NLRC5 expressions in patients with relapsing-remitting multiple sclerosis: is there any correlation? Genes Immun 2021. [PMID: 34782775 DOI: 10.1038/s41435-021-00154-4] [Reference Citation Analysis]
4 Tabnak P, Mafakheri A, Haji Emsailpoor Z, Kazemi T, Shekari N. Regulatory interplay between microRNAs and WNT pathway in glioma. Biomed Pharmacother 2021;143:112187. [PMID: 34560532 DOI: 10.1016/j.biopha.2021.112187] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lv L, Wei Q, Wang Z, Zhao Y, Chen N, Yi Q. Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma. Front Bioeng Biotechnol 2021;9:690186. [PMID: 34307322 DOI: 10.3389/fbioe.2021.690186] [Reference Citation Analysis]
6 Shklovskaya E, Rizos H. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. Int J Mol Sci 2021;22:6741. [PMID: 34201655 DOI: 10.3390/ijms22136741] [Reference Citation Analysis]
7 Zhang L, Jiao C, Liu L, Wang A, Tang L, Ren Y, Huang P, Xu J, Mao D, Liu L. NLRC5: A Potential Target for Central Nervous System Disorders. Front Immunol 2021;12:704989. [PMID: 34220868 DOI: 10.3389/fimmu.2021.704989] [Reference Citation Analysis]
8 Pilsworth JA, Cochrane DR, Neilson SJ, Moussavi BH, Lai D, Munzur AD, Senz J, Wang YK, Zareian S, Bashashati A, Wong A, Keul J, Staebler A, van Meurs HS, Horlings HM, Kommoss S, Kommoss F, Oliva E, Färkkilä AE, Gilks B, Huntsman DG. Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease. J Pathol Clin Res 2021;7:243-52. [PMID: 33428330 DOI: 10.1002/cjp2.198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Ju Q, Li X, Zhang H, Yan S, Li Y, Zhao Y. NFE2L2 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltration in Brain Lower Grade Glioma: A Pan-Cancer Analysis. Oxid Med Cell Longev 2020;2020:3580719. [PMID: 33101586 DOI: 10.1155/2020/3580719] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
10 Cornel AM, Mimpen IL, Nierkens S. MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers (Basel) 2020;12:E1760. [PMID: 32630675 DOI: 10.3390/cancers12071760] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 16.0] [Reference Citation Analysis]